This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Proteasomal ubiquitin receptor ADRM1.
Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. Within the complex, functions as a proteasomal ubiquitin receptor.
Human | |
---|---|
Gene Name: | ADRM1 |
Uniprot: | Q16186 |
Entrez: | 11047 |
Belongs to: |
---|
ADRM1 family |
000 surface antigen; 110 kDa cell membrane glycoprotein; adhesion regulating molecule 1; Adhesion-regulating molecule 1; ARM1; ARM-1; Gp110; GP110hRpn13; M(r) 110; MGC29536; proteasomal ubiquitin receptor ADRM1; Proteasome regulatory particle non-ATPase 13; regulatory particle non-ATPase 13; Rpn13 homolog; Rpn13
Mass (kDA):
42.153 kDA
Human | |
---|---|
Location: | 20q13.33 |
Sequence: | 20; NC_000020.11 (62302061..62308862) |
Cytoplasm. Nucleus.
ADRM1 regulates many different pathways within the body. It is also a component of the DNA, which is why Boster antibodies are so valuable to researchers. Boster antibodies are highly specific to ADRM1 and are validated on Western Blotting, Immunohistochemistry, and ELISA. These antibodies are very effective in a wide range of applications and have excellent reproducibility.
ADRM1 is expressed in the surface of several eukaryotic cellular cells, including Ovarian carcinoma. ADRM1 plays a critical role in a variety of biological functions. The protein also plays an important role in the production retinoic, a hormone which can be dangerous for human health. Interestingly, ADRM1 knockdown has been shown to cause an increased risk of developing ovarian cancer.
ADRM1 is an interaction protein with the proteasome. This regulates protein degradation. The overexpression of ADRM1 is associated with reduced survival and recurrence of ovarian cancer. ADRM1 may also be associated with the ovarian cancer protein, HAX1. Overexpression is associated to an increased risk for ovarian cancer recurrences and metastasis.
Boster's antiBax antibodies are investigational monoclonal antibodies that use the ADRM1 marker. This marker blocks the entry of viruses to the human body. It provides a protective alternative to COVID-19 vaccination failure and has a 9-12 month duration of action. This antibody must only be administered intravenously. It should be monitored in an infusion center. However, it can be administered intramuscularly. This has a significant operational advantage.
PMID: 8033103 by Shimada S., et al. Molecular cloning and characterization of the complementary DNA of an M(r) 110,000 antigen expressed by human gastric carcinoma cells and upregulated by gamma-interferon.
PMID: 16990800 by Hamazaki J., et al. A novel proteasome-interacting protein recruits the deubiquitinating enzyme UCH37 to 26S proteasomes.